Report Overview

Indian Pulmonary Artery Hypertension (PAH) Drugs Market size was valued at USD XX billion in 2019 and is expected to expand at a compound annual growth rate (CAGR) of XX% from 2019 to 2028.

Pulmonary Arterial Hypertension (PAH) is one of the rare diseases, which usually affects the pulmonary arteries. High blood pressure in the lungs is called pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). It is characterized by narrowed and blocked arteries and capillaries. This rare disease can grow worse over the period and may result to death if left untreated. The symptoms of pulmonary arterial hypertension include shortness of breath (dyspnea) especially during exercise, chest pain, and fainting. The increase in the number of geriatrics leads to consequences which is several cases includes complications related to pulmonary arterial hypertensions. The technological advancements are also steadily focusing on the identification of new molecular pathways which contributes to development of better treatments possible over the forecast period.



Market Drivers

The increasing prevalence of cardiovascular and pulmonary disorders is one of the key factors driving the growth of the market. Furthermore, the rising geriatric population that is more susceptible to such medical ailments is providing a boost to the market growth.
Besides this, changes in lifestyles, such as excessive alcohol consumption, a lack of physical activity, and unhealthy dietary patterns, have enhanced the risks of hypertension and high blood pressure. This, along with the development of novel orphan drugs and technologically advanced devices for the treatment of PAH, is favoring the market growth.
Other factors, including increasing awareness among the masses regarding the available treatment alternatives for PAH, and improving healthcare infrastructure across the nation, are expected to drive the market further.